Skip to main content
Fig. 5 | BMC Biology

Fig. 5

From: Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity

Fig. 5

Disruption of the oncogenic BRAFV600E mutation with AsCas12a variants in human A375 melanoma cells. a Tag-seq assessing the editing specificity of AsCas12a-WT and AsCas12a variants for BRAF with WT- and mut-sgRNAs in HEK-293T Cell (BRAF +/+) and A375 Cell (BRAF V600E/V600E). b Flow cytometry detecting the cells apoptosis induced by disrupting the BRAFV600E mutation using AsCas12a-WT, AsCas12a-RKA, and AsCas12a-HF. Blank, A375 cells without treatment. NC, AsCas12a-WT, AsCas12a-RKA, and AsCas12a-HF mix + sgRNA-EGFP. WT/RKA/HF, AsCas12a-WT/AsCas12a-RKA/AsCas12a-HF + mut-BRAF-sgRNA. Mean values are presented with SEM, n=3 independent experiments

Back to article page